Risk of functional impairment in facioscapulohumeral muscular dystrophy

Muscle and Nerve

Volumn 49, Issue 4, 2014, Pages 520-527

  Statland, Jeffrey M ^a   Tawil, Rabi ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

D4Z4 contraction; Facioscapulohumeral dystrophy; Functional impairment; Muscular dystrophy; Neuromuscular disorders

Indexed keywords

ADULT; ARTICLE; COHORT ANALYSIS; CONFIDENCE INTERVAL; FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY; FEMALE; FUNCTIONAL DISEASE; HEARING AID; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MUSCLE CONTRACTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; WHEELCHAIR;

D4Z4 CONTRACTION; FACIOSCAPULOHUMERAL DYSTROPHY; FUNCTIONAL IMPAIRMENT; MUSCULAR DYSTROPHY; NEUROMUSCULAR DISORDERS;

ADULT; AGED; COHORT STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; MUSCULAR DYSTROPHY, FACIOSCAPULOHUMERAL; QUESTIONNAIRES; REGISTRIES; RETROSPECTIVE STUDIES; RISK FACTORS; WHEELCHAIRS;

EID: 84896124521     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.23949     Document Type: Article

References (31)

1. Flanigan KM, Coffeen CM, Sexton L, Stauffer D, Brunner S, Leppert MF. Genetic characterization of a large, historically significant Utah kindred with facioscapulohumeral dystrophy. Neuromuscul Disord 2001;11:525-529.
2. Mostacciuolo ML, Pastorello E, Vazza G, Miorin M, Angelini C, Tomelleri G, et al. Facioscapulohumeral muscular dystrophy: epidemiological and molecular study in a north-east Italian population sample. Clin Genet 2009;75:550-555.
3. Johnson NE, Quinn C, Eastwood E, Tawil R, Heatwole CR. Patient identified disease burden in fascioscapulohumeral muscular dystrophy. Muscle and Nerve 2012;46:951-953.
4. Lamperti C, Fabbri G, Vercelli L, D'Amico R, Frusciante R, Bonifazi E, et al. A standardized clinical evaluation of patients affected by facioscapulohumeral muscular dystrophy: the FSHD clinical score. Muscle Nerve 2010;42:213-217.
5. Lunt PW, Jardine PE, Koch MC, Maynard J, Osborn M, Williams M, et al. Correlation between fragment size at D4F104S1 and age at onset or at wheelchair use, with a possible generational effect, accounts for much phenotypic variation in 4q35-facioscapulohumeral muscular dystrophy (FSHD). Hum Mol Genet 1995;4:951-958.
6. Padberg GW.Facioscapulohumeral disease. Thesis. Leiden, the Netherlands: University of Leiden 1982.
7. Padberg GW, Frants RR, Brouwer OF, Wijmenga C, Bakker E, Sandkuijl LA. Facioscapulohumeral muscular dystrophy in the Dutch population. Muscle Nerve 1995;2:S81-S84.
8. Ricci E, Galluzzi G, Deidda G, Cacurri S, Colantoni L, Merico B, et al. Progress in the molecular diagnosis of facioscapulohumeral muscular dystrophy and correlation between the number of KpnI repeats at the 4q35 locus and clinical phenotype. Ann Neurol 1999;45:751-757.
9. Tawil R, McDermott MP, Mendell JR, Kissel J, Griggs RC. Facioscapulohumeral muscular dystrophy (FSHD): design of natural history study and results of baseline testing. FSH-DY Group. Neurology 1994;44(Pt 1):442-446.
10. FSH-DY. A prospective, quantitative study of the natural history of facioscapulohumeral muscular dystrophy (FSHD): implications for therapeutic trials. The FSH-DY Group. Neurology 1997;48:38-46.
11. Stubgen JP, Stipp A. Facioscapulohumeral muscular dystrophy: a prospective study of weakness and functional impairment. J Neurol 2010;257:1457-1464.
12. Lemmers RJ, van der Vliet PJ, Klooster R, Sacconi S, Camano P, Dauwerse JG, et al. A unifying genetic model for facioscapulohumeral muscular dystrophy. Science 2010;329:1650-1653.
13. de Greef JC, Frants RR, van der Maarel SM. Epigenetic mechanisms of facioscapulohumeral muscular dystrophy. Mutat Res 2008;647:94-102.
14. van Deutekom JC, Wijmenga C, van Tienhoven EA, Gruter AM, Hewitt JE, Padberg GW, et al. FSHD associated DNA rearrangements are due to deletions of integral copies of a 3.2 kb tandemly repeated unit. Hum Mol Genet 1993;2:2037-2042.
15. Wijmenga C, Hewitt JE, Sandkuijl LA, Clark LN, Wright TJ, Dauwerse HG, et al. Chromosome 4q DNA rearrangements associated with facioscapulohumeral muscular dystrophy. Nat Genet 1992;2:26-30.
16. Lemmers RJ, Tawil R, Petek LM, Balog J, Block GJ, Santen GW, et al. Digenic inheritance of an SMCHD1 mutation and an FSHD-permissive D4Z4 allele causes facioscapulohumeral muscular dystrophy type 2. Nat Genet 2012;44:1370-1374.
17. Fitzsimons RB, Gurwin EB, Bird AC. Retinal vascular abnormalities in facioscapulohumeral muscular dystrophy. A general association with genetic and therapeutic implications. Brain 1987;110(Pt 3):631-648.
18. Padberg GW, Brouwer OF, de Keizer RJ, Dijkman G, Wijmenga C, Grote JJ, et al. On the significance of retinal vascular disease and hearing loss in facioscapulohumeral muscular dystrophy. Muscle Nerve 1995;2:S73-S80.
19. Hilbert JE, Kissel JT, Luebbe EA, Martens WB, McDermott MP, Sanders DB, et al. If you build a rare disease registry, will they enroll and will they use it? Methods and data from the National Registry of Myotonic Dystrophy (DM) and Facioscapulohumeral Muscular Dystrophy (FSHD). Contemp Clin Trials 2012;33:302-311.
20. Woodward M. Epidemiology: study design and analysis. New York: Chapman and Hall/CRC; 2005.
21. Walker GA, Shostak J. Common statistical methods for clinical research. Cary, NC: SAS Institute Inc.; 2010. p 361-397.
22. Padua L, Aprile I, Frusciante R, Iannaccone E, Rossi M, Renna R, et al. Quality of life and pain in patients with facioscapulohumeral muscular dystrophy. Muscle Nerve 2009;40:200-205.
23. D'Angelo MG, Romei M, Lo Mauro A, Marchi E, Gandossini S, Bonato S, et al. Respiratory pattern in an adult population of dystrophic patients. J Neurol Sci 2011;306:54-61.
24. Kilmer DD, Abresch RT, McCrory MA, Carter GT, Fowler WM Jr, Johnson ER, et al. Profiles of neuromuscular diseases. Facioscapulohumeral muscular dystrophy. Am J Phys Med Rehabil 1995;74(Suppl):S131-S139.
25. Stubgen JP, Schultz C. Lung and respiratory muscle function in facioscapulohumeral muscular dystrophy. Muscle Nerve 2009;39:729-734.
26. Wohlgemuth M, van der Kooi EL, van Kesteren RG, van der Maarel SM, Padberg GW. Ventilatory support in facioscapulohumeral muscular dystrophy. Neurology 2004;63:176-178.
27. Laforet P, de Toma C, Eymard B, Becane HM, Jeanpierre M, Fardeau M, et al. Cardiac involvement in genetically confirmed facioscapulohumeral muscular dystrophy. Neurology 1998;51:1454-1456.
28. Trevisan CP, Pastorello E, Ermani M, Angelini C, Tomelleri G, Tonin P, et al. Facioscapulohumeral muscular dystrophy: a multicenter study on hearing function. Audiol Neurootol 2008;13:1-6.
29. Nakagawa M, Matsuzaki T, Higuchi I, Fukunaga H, Inui T, Nagamitsu S, et al. Facioscapulohumeral muscular dystrophy: clinical diversity and genetic abnormalities in Japanese patients. Intern Med 1997;36:333-339.
30. Trevisan CP, Pastorello E, Tomelleri G, Vercelli L, Bruno C, Scapolan S, et al. Facioscapulohumeral muscular dystrophy: hearing loss and other atypical features of patients with large 4q35 deletions. Eur J Neurol 2008;15:1353-1358.
31. Forrest CB, Bartek RJ, Rubinstein Y, Groft SC. The case for a global rare-diseases registry. Lancet 2011;377:1057-1059.